Pharming Group reports first quarter 2025 financial results and provides business update First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting continued momentum and the product’s unique position in the on-demand HAE marketJoenja® (leniolisib) volume increase by 18% and revenue increased by 9% to US$10.5 million, compared to the first quarter of 2024, with accelerating patient uptake compared to the prior few quartersOperating profit, adju...
Eramet : Informations relatives au nombre total de droits de vote et d’actions au 30 avril 2025 Dénomination sociale de l'émetteur : ERAMET SA10 boulevard de Grenelle75015 Paris632 045 381 RCS PARIS Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 223-8 II du code de commerce et l’article 223-16 du règlement général de l’Autorité des marchés financiers N° LEI : 549300LUH78PG2MP6N64 Date d'arrêté des informationsNombre total d'actions composant le capitalNombre total de droits de vote 30 avril 202528 755 047Nombre de droits de vote théoriques...
A director at Eramet bought 7,500 shares at 48.360EUR and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...
Availability of the documents of the Ordinary and Extraordinary Shareholders’ General Meeting to be held on May 26th, 2025 Paris, May 5th, 2025, 5:45 pm PRESS RELEASE Availability of the documents of the Ordinary and Extraordinary Shareholders’ General Meeting to be held on May 26th, 2025 Eramet’s shareholders are invited to participate in the Ordinary and Extraordinary Shareholder’s General Meeting, which will take place on: Monday, May 26th, 2025, at 10:00 a.m. (Paris time), at Eramet’s head office, 10 boulevard de Grenelle 75015 Paris. Detailed participation procedures are outlined...
Mise à disposition des documents pour l’Assemblée Générale Ordinaire et Extraordinaire du 26 mai 2025 Paris, le 5 mai 2025, 17h45 COMMUNIQUE DE PRESSE Mise à disposition des documents pour l’Assemblée Générale Ordinaire et Extraordinaire du 26 mai 2025 Les actionnaires de la société sont invités à participer à l’Assemblée Générale Ordinaire et Extraordinaire d’Eramet qui se tiendra le : Lundi 26 mai 2025 à 10h00, au siège social d’Eramet, 10 boulevard de Grenelle, 75015 Paris. Les modalités détaillées de participation figurent notamment dans la brochure de convocation et seront préci...
Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director Leiden, the Netherlands, April 30, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company’s 2025 Annual General Meeting of Shareholders (the “AGM”) will be held on Wednesday June 11, 2025, at 14:00 CEST. The Notice to Convene, Explanatory Notes, Proxy and other meeting documents for the AGM can be found on the Company’s website under Investors/Shareholder Meetings. The Board of Directors has decide...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.